20 September 2020 : Meta-Analysis
Efficacy and Toxicity of Adjuvant Therapies for High-Risk Endometrial Cancer in Stage I–III: A Systematic Review and Network Meta-Analysis
Mengyin Ao12ABCDEF, Ting Ding12BF, Dan Tang12E, Mingrong Xi12E*DOI: 10.12659/MSM.925595
Med Sci Monit 2020; 26:e925595
Table 1 Characteristics of included randomized clinical trials.
| Author | Sub-category | Location | FIGO stage | Intervention | Sample size | Age, years median (range) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T1 | T2 | Total | T1 | T2 | ||||
| Randall et al. | GOG-249 | USA | I–II | A | B | 301 | 300 | 601 | 63 (NR) | 65 (NR) |
| Hogberg et al. (1) | NSGO-RORTC | Sweden | I–IIIC | A | C | 191 | 187 | 378 | 64 (44–79) | 64 (38–83) |
| Hogberg et al. (2) | Mango | Sweden | II–III | A | C | 76 | 80 | 156 | 59 (42–78) | 58 (39–77) |
| Morrow et al. | GOG-34 | USA | I–II occult | A | C | 89 | 92 | 181 | NR | NR |
| Kuoppala et al. | NR | Finland | I–IIIA | A | C | 72 | 84 | 156 | 74 (47–86) | 73 (47–85) |
| de Boer et al. | PORTEC-3 | France, Italy, Canada | I–III | A | C | 330 | 330 | 660 | 62 (NR) | 62 (NR) |
| Creutzberg et al. | PORTEC-1 | Netherlands | I–IIIC | A | D | 354 | 360 | 714 | 66 (41–85) | 66 (43–90) |
| Keys et al. | GOG-99 | USA | I–II occult | A | D | 190 | 202 | 392 | 63 (NR) | 63 (NR) |
| Blake et al. | ASTEC/EN5 | UK, Canada, Poland | I–IIB | A | D | 452 | 453 | 905 | 65 (36–88) | 66 (31–88) |
| Susumu et al. | JGOG | Japan | IC–IIIC | A | E | 193 | 192 | 385 | NR | NR |
| Maggi et al. | NR | Italy | IC–IIIC | A | E | 166 | 174 | 340 | 62 (NR) | 63 (NR) |
| Sorbe et al. | NR | Sweden | IA–IC | F | G | 264 | 263 | 527 | NR | NR |
| Sunil et al. | NR | India | IA–IB | F | G | 25 | 25 | 50 | NR | NR |
| Nout et al. | PORTEC-2 | Dutch | IB–IIA | A | G | 214 | 213 | 427 | 69 (NR) | 70 (NR) |
| A – pelvic radiotherapy; B – vaginal cuff brachytherapy and chemotherapy; C – pelvic radiotherapy and chemotherapy; D – No further treatment; E – chemotherapy; F – pelvic radiotherapy and vaginal brachytherapy; G – vaginal brachytherapy. a Based on FIGO 2009 classification; b based on FIGO 1988 classification; c based on FIGO 2009 classification; NR – not reported. | ||||||||||